MIP-1 Alpha and Myeloma Bone Disease
Authors:
- 1 January 2004
- book chapter
- Published by Springer Nature
- Vol. 118, 83-100
Abstract
Multiple myeloma (MM) is a severely debilitating, incurable, and uniformly fatal neoplastic disease of B cell origin ( Barker et al., 1993 ). Although much effort has been directed at devising effective treatments for these patients, their prognosis and survival have been relatively unchanged over the last 30 years, except for a subgroup of patients undergoing successful autologous or allogeneic stem cell transplantation ( Gahrton et al., 2001 ). The major source of morbidity and possible mortality associated with MM is osteolytic lesions throughout the axial skeleton ( Coleman, 1997 ). Lytic bone lesions occur in over 70–80% of these patients (Anderson, 1999), and are frequently associated with severe bone pain and pathologic fractures. Up to one third of the patients develop hypercalcemia. The bone lesions result from increased osteoclastic bone resorption that occurs adjacent to the myeloma cells and not in areas of normal bone marrow ( Anderson et al., 2002 ). These data suggest that locally acting factors produced by myeloma cells induce extensive bone destruction. Consistent with this hypothesis is the finding that cultures of human myeloma cells in vitro produce several osteoclast activating factors (OAFs), including TNF-α ( Garret et al., 1987 ; Sati et al., 1999 , IL-1-ß Lacy et al., 1999 ; Lust et al., 1999 ), and IL-6 ( Bataille et al., 1995 ; Epstein et al., 1992 ; Iwasaki et al., 1999 ). However, none of these cytokines appears to be clearly responsible for the bone destruction in vivo. The increase in osteoclast (OCL) bone resorption in myeloma is usually associated with a marked impairment in osteoblast function Alexandrakis et al., 2002 ). Alkaline phosphatase activity in the serum is decreased or in the normal range, unlike patients with other types of osteolytic bone disease, and radionuclide scans do not show evidence of increased uptake in over 50% of patients with osteolytic lesions, indicating impaired osteoblast responses to the increase in bone resorption.Keywords
This publication has 42 references indexed in Scilit:
- Multiple MyelomaHematology-American Society Hematology Education Program, 2002
- Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myelomaBlood, 2001
- Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligandBlood, 2001
- Macrophage-Inflammatory Protein-1α Regulates Preosteoclast Differentiationin VitroBiochemical and Biophysical Research Communications, 1999
- Differential Use of Very Late Antigen-4 and -5 Integrins by Hematopoietic Precursors and Myeloma Cells to Adhere to Transforming Growth Factor-β1-treated Bone Marrow StromaJournal of Biological Chemistry, 1998
- Chemokines regulate cellular polarization and adhesion receptor redistribution during lymphocyte interaction with endothelium and extracellular matrix. Involvement of cAMP signaling pathway.Journal of Cell Biology, 1995
- Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigmCell, 1994
- Multiple myeloma: The biology of malignant plasma cellsBlood Reviews, 1993
- SCIMIP-1α: A potent stem cell inhibitor with potential roles in developmentDevelopmental Biology, 1992
- Production of Lymphotoxin, a Bone-Resorbing Cytokine, by Cultured Human Myeloma CellsNew England Journal of Medicine, 1987